Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ANIK's Cash to Debt is ranked higher than
97% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ANIK: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ANIK' s Cash to Debt Range Over the Past 10 Years
Min: 1.5  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.90
ANIK's Equity to Asset is ranked higher than
83% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ANIK: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
ANIK' s Equity to Asset Range Over the Past 10 Years
Min: 0.49  Med: 0.78 Max: 0.94
Current: 0.9
0.49
0.94
Interest Coverage No Debt
ANIK's Interest Coverage is ranked higher than
95% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ANIK: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ANIK' s Interest Coverage Range Over the Past 10 Years
Min: 38.66  Med: 5128.38 Max: 9999.99
Current: No Debt
38.66
9999.99
F-Score: 5
Z-Score: 16.95
M-Score: -2.84
WACC vs ROIC
16.80%
38.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 50.56
ANIK's Operating margin (%) is ranked higher than
96% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ANIK: 50.56 )
Ranked among companies with meaningful Operating margin (%) only.
ANIK' s Operating margin (%) Range Over the Past 10 Years
Min: 11.81  Med: 21.47 Max: 58.19
Current: 50.56
11.81
58.19
Net-margin (%) 32.25
ANIK's Net-margin (%) is ranked higher than
93% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ANIK: 32.25 )
Ranked among companies with meaningful Net-margin (%) only.
ANIK' s Net-margin (%) Range Over the Past 10 Years
Min: 7.77  Med: 16.82 Max: 36.29
Current: 32.25
7.77
36.29
ROE (%) 14.96
ANIK's ROE (%) is ranked higher than
88% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ANIK: 14.96 )
Ranked among companies with meaningful ROE (%) only.
ANIK' s ROE (%) Range Over the Past 10 Years
Min: 5.16  Med: 11.29 Max: 24.43
Current: 14.96
5.16
24.43
ROA (%) 13.66
ANIK's ROA (%) is ranked higher than
93% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ANIK: 13.66 )
Ranked among companies with meaningful ROA (%) only.
ANIK' s ROA (%) Range Over the Past 10 Years
Min: 3.27  Med: 7.61 Max: 21.89
Current: 13.66
3.27
21.89
ROC (Joel Greenblatt) (%) 73.35
ANIK's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ANIK: 73.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ANIK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 13.35  Med: 40.48 Max: 222.6
Current: 73.35
13.35
222.6
Revenue Growth (3Y)(%) 13.70
ANIK's Revenue Growth (3Y)(%) is ranked higher than
71% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ANIK: 13.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ANIK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.5  Med: 10.10 Max: 26.7
Current: 13.7
-4.5
26.7
EBITDA Growth (3Y)(%) 49.00
ANIK's EBITDA Growth (3Y)(%) is ranked higher than
91% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ANIK: 49.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ANIK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.1  Med: 38.80 Max: 95.7
Current: 49
-65.1
95.7
EPS Growth (3Y)(%) 59.70
ANIK's EPS Growth (3Y)(%) is ranked higher than
94% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ANIK: 59.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ANIK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: 24.80 Max: 75.8
Current: 59.7
-66.2
75.8
» ANIK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ANIK Guru Trades in Q1 2015

John Burbank 10,047 sh (New)
Joel Greenblatt 278,578 sh (-19.76%)
Jim Simons 112,500 sh (-47.13%)
» More
Q2 2015

ANIK Guru Trades in Q2 2015

Jim Simons 117,200 sh (+4.18%)
John Burbank Sold Out
Joel Greenblatt 258,483 sh (-7.21%)
» More
Q3 2015

ANIK Guru Trades in Q3 2015

Jim Simons 53,600 sh (-54.27%)
Joel Greenblatt 89,187 sh (-65.50%)
» More
Q4 2015

ANIK Guru Trades in Q4 2015

Ken Fisher 14,124 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ANIK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.70
ANIK's P/E(ttm) is ranked higher than
68% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 32.30 vs. ANIK: 20.70 )
Ranked among companies with meaningful P/E(ttm) only.
ANIK' s P/E(ttm) Range Over the Past 10 Years
Min: 8.66  Med: 20.43 Max: 46.11
Current: 20.7
8.66
46.11
Forward P/E 21.10
ANIK's Forward P/E is ranked lower than
55% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 19.53 vs. ANIK: 21.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.70
ANIK's PE(NRI) is ranked higher than
68% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 32.00 vs. ANIK: 20.70 )
Ranked among companies with meaningful PE(NRI) only.
ANIK' s PE(NRI) Range Over the Past 10 Years
Min: 8.57  Med: 20.41 Max: 46.32
Current: 20.7
8.57
46.32
P/B 2.80
ANIK's P/B is ranked higher than
56% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. ANIK: 2.80 )
Ranked among companies with meaningful P/B only.
ANIK' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 2.37 Max: 5.26
Current: 2.8
0.58
5.26
P/S 6.70
ANIK's P/S is ranked higher than
61% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. ANIK: 6.70 )
Ranked among companies with meaningful P/S only.
ANIK' s P/S Range Over the Past 10 Years
Min: 1  Med: 3.91 Max: 9.2
Current: 6.7
1
9.2
PFCF 15.94
ANIK's PFCF is ranked higher than
70% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 30.47 vs. ANIK: 15.94 )
Ranked among companies with meaningful PFCF only.
ANIK' s PFCF Range Over the Past 10 Years
Min: 10.45  Med: 19.62 Max: 1445
Current: 15.94
10.45
1445
POCF 14.81
ANIK's POCF is ranked higher than
70% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. ANIK: 14.81 )
Ranked among companies with meaningful POCF only.
ANIK' s POCF Range Over the Past 10 Years
Min: 8.95  Med: 18.86 Max: 429.5
Current: 14.81
8.95
429.5
EV-to-EBIT 9.74
ANIK's EV-to-EBIT is ranked higher than
70% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 23.89 vs. ANIK: 9.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ANIK' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.8  Med: 10.60 Max: 37.9
Current: 9.74
1.8
37.9
EV-to-EBITDA 8.93
ANIK's EV-to-EBITDA is ranked higher than
69% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.19 vs. ANIK: 8.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
ANIK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.4  Med: 9.20 Max: 34
Current: 8.93
1.4
34
PEG 0.44
ANIK's PEG is ranked higher than
92% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. ANIK: 0.44 )
Ranked among companies with meaningful PEG only.
ANIK' s PEG Range Over the Past 10 Years
Min: 0.29  Med: 0.56 Max: 30.25
Current: 0.44
0.29
30.25
Shiller P/E 42.11
ANIK's Shiller P/E is ranked higher than
62% of the 50 Companies
in the Global Biotechnology industry.

( Industry Median: 51.54 vs. ANIK: 42.11 )
Ranked among companies with meaningful Shiller P/E only.
ANIK' s Shiller P/E Range Over the Past 10 Years
Min: 13.92  Med: 40.72 Max: 129.55
Current: 42.11
13.92
129.55
Current Ratio 12.71
ANIK's Current Ratio is ranked higher than
82% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ANIK: 12.71 )
Ranked among companies with meaningful Current Ratio only.
ANIK' s Current Ratio Range Over the Past 10 Years
Min: 2.84  Med: 6.43 Max: 23.7
Current: 12.71
2.84
23.7
Quick Ratio 11.79
ANIK's Quick Ratio is ranked higher than
80% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ANIK: 11.79 )
Ranked among companies with meaningful Quick Ratio only.
ANIK' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 5.55 Max: 21.67
Current: 11.79
1.21
21.67
Days Inventory 224.30
ANIK's Days Inventory is ranked lower than
74% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. ANIK: 224.30 )
Ranked among companies with meaningful Days Inventory only.
ANIK' s Days Inventory Range Over the Past 10 Years
Min: 98.12  Med: 139.70 Max: 204.07
Current: 224.3
98.12
204.07
Days Sales Outstanding 99.96
ANIK's Days Sales Outstanding is ranked lower than
69% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ANIK: 99.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ANIK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.28  Med: 79.86 Max: 109.78
Current: 99.96
25.28
109.78
Days Payable 39.98
ANIK's Days Payable is ranked lower than
63% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. ANIK: 39.98 )
Ranked among companies with meaningful Days Payable only.
ANIK' s Days Payable Range Over the Past 10 Years
Min: 20.94  Med: 51.70 Max: 169.68
Current: 39.98
20.94
169.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.20
ANIK's Price/Net Cash is ranked higher than
50% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.23 vs. ANIK: 5.20 )
Ranked among companies with meaningful Price/Net Cash only.
ANIK' s Price/Net Cash Range Over the Past 10 Years
Min: 0.48  Med: 7.37 Max: 79.94
Current: 5.2
0.48
79.94
Price/Net Current Asset Value 3.84
ANIK's Price/Net Current Asset Value is ranked higher than
58% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 4.85 vs. ANIK: 3.84 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ANIK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.34  Med: 4.58 Max: 40.16
Current: 3.84
0.34
40.16
Price/Tangible Book 3.12
ANIK's Price/Tangible Book is ranked higher than
57% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ANIK: 3.12 )
Ranked among companies with meaningful Price/Tangible Book only.
ANIK' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.29  Med: 2.68 Max: 13.19
Current: 3.12
0.29
13.19
Price/Projected FCF 1.34
ANIK's Price/Projected FCF is ranked higher than
81% of the 150 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. ANIK: 1.34 )
Ranked among companies with meaningful Price/Projected FCF only.
ANIK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.48  Med: 2.10 Max: 57.5
Current: 1.34
0.48
57.5
Price/Median PS Value 1.74
ANIK's Price/Median PS Value is ranked lower than
80% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ANIK: 1.74 )
Ranked among companies with meaningful Price/Median PS Value only.
ANIK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.94 Max: 2.44
Current: 1.74
0.13
2.44
Price/Peter Lynch Fair Value 0.83
ANIK's Price/Peter Lynch Fair Value is ranked higher than
85% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. ANIK: 0.83 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ANIK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.37  Med: 0.82 Max: 5.53
Current: 0.83
0.37
5.53
Price/Graham Number 1.69
ANIK's Price/Graham Number is ranked higher than
53% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. ANIK: 1.69 )
Ranked among companies with meaningful Price/Graham Number only.
ANIK' s Price/Graham Number Range Over the Past 10 Years
Min: 0.49  Med: 1.65 Max: 15.68
Current: 1.69
0.49
15.68
Earnings Yield (Greenblatt) (%) 10.30
ANIK's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ANIK: 10.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ANIK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.6  Med: 9.50 Max: 56.4
Current: 10.3
2.6
56.4
Forward Rate of Return (Yacktman) (%) 46.35
ANIK's Forward Rate of Return (Yacktman) (%) is ranked higher than
94% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. ANIK: 46.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ANIK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -10.4  Med: 4.80 Max: 54.8
Current: 46.35
-10.4
54.8

More Statistics

Revenue(Mil) $85
EPS $ 1.82
Beta1.99
Short Percentage of Float18.30%
52-Week Range $30.93 - 45.35
Shares Outstanding(Mil)14.64

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 90 94 104
EPS($) 1.82 1.54 1.79
EPS without NRI($) 1.82 1.54 1.79

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AKP.Germany,
Anika Therapeutics Inc was incorporated in 1992 as a Massachusetts company. The Company develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid, or HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its biophysical and biochemical properties, HA performs physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells. The Company through its subsidiary has over 20 products currently commercialized, mainly in Europe. These products are made from hyaluronic acid, based on two technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Both technologies are protected by a portfolio of owned and licensed patents. The Company offers therapeutic products in various areas which include: Orthobiologics, Dermal, Surgical, Ophthalmic and Veterinary. Its Orthobiologics products consist of joint health and orthopedic products. These products are used in a range of treatments from providing relief from the pain of osteoarthritis, to regenerating damaged tissue such as cartilage defects. Its joint health products include ORTHOVISC, ORTHOVISC mini, and MONOVISC. ORTHOVISC is available in the U.S., Canada, Turkey and other international markets for the treatment of osteoarthritis of the knee, and in Europe for the treatment of osteoarthritis in all joints. Its Dermal products consist of wound care products, based on the HYAFF technology, and aesthetic dermal fillers. The HYAFF technology offers products for the treatment of skin wounds, ranging from burns to diabetic ulcers. The products cover a variety of wound treatment solutions including debridement agents,therapies to aid healing and skin substitutes. Its ophthalmic business includes HA viscoelastic products used in ophthalmic surgery. These products include AMVISC and AMVISC Plus product line, STAARVISC-IITM, Optivisc, AnikaVisc and AnikaVisc Plus which are injectable, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. Its surgical business consists of products used to prevent surgical adhesions, and to treat ENT disorders. Hyalobarrier is a clinically post-operative adhesion barrier for use in the abdomino-pelvic area. The product is currently commercialized in Europe, the Middle East and certain Asian countries through a distribution network, but is not approved in the U.S. INCERT, approved for sale in Europe, Turkey, and Malaysia. It is chemically modified, cross-linked HA product for the prevention of spinal post-surgical adhesions. The Company along with its subsidiary offers products used in connection with the treatment of ENT disorders. The products are Merogel, a woven fleece nasal
» More Articles for ANIK

Headlines

Articles On GuruFocus.com
Four Stocks With Growing EPS Near Their 52-Week Lows - Part II Jul 02 2015 
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Nov 03 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Anika Therapeutics Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : February 4, 2016 Feb 04 2016
Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : February 4, 2016 Feb 04 2016
Ultragenyx Pharmaceutical (RARE) in Focus: Stock Tumbles 11.2% Jan 14 2016
How Anika Therapeutics (ANIK) Stock Stands Out in a Strong Industry Jan 14 2016
Weakness Seen in Chiasma (CHMA): Stock Slumps 16% Jan 12 2016
uniQure N.V. (QURE) Shows Strength: Stock Moves Up 5.3% Jan 11 2016
Anika (ANIK) Starts Enrolment in Phase III HyaloFast Study Dec 30 2015
​Bedford firm Anika Therapeutics tests device to heal damaged cartilage in the knee Dec 30 2015
Anika Therapeutics, Inc. Announces First Patient Enrolled in FastTRACK Phase III HYALOFAST® Study Dec 29 2015
Anika Therapeutics, Inc. Announces First Patient Enrolled in FastTRACK Phase III HYALOFAST® Study Dec 29 2015
Evogene (EVGN) Shows Strength: Stock Moves Up 9% Dec 28 2015
Anika Therapeutics Announces Decision to Proceed with CINGAL® Premarket Review Through FDA's Center... Dec 09 2015
ANIKA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in... Dec 09 2015
Anika Therapeutics Announces Decision to Proceed with CINGAL® Premarket Review Through FDA’s... Dec 09 2015
ANIKA THERAPEUTICS, INC. Financials Dec 08 2015
Anika (ANIK): Moving Average Crossover Alert Dec 02 2015
Axovant Sciences (AXON) Jumps: Stock Moves Up 9.8% Dec 01 2015
Why Anika Therapeutics (ANIK) Stock Might be a Great Pick Nov 30 2015
Should You Buy Chuy’s Holdings Inc (CHUY)? Nov 26 2015
Why Anika Therapeutics (ANIK) Could Be Positioned for a Surge? Nov 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK